ArticleAmerican journal of veterinary research2025
Equine bone marrow aspirate and bone marrow aspirate concentrate are enriched with interleukin-1 receptor antagonist protein.
Article in American journal of veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Objective: To analyze the cellular, growth factor, and cytokine composition of equine sternal bone marrow aspirate (BMA) and laboratory-centrifuged BMA concentrate (BMAC). Methods: This was an in vitro experimental study. Cellular composition, growth factors (IGF-I, VEGF, PDGF, TGF-β1), and cytokines (IL-6, IL-10, tumor necrosis factor-α (TNF-α), and IL-1 receptor antagonist protein [IL-1Ra]) were quantified using a standard automated hematology analyzer and ELISA methods, respectively, in donor-matched BMA, BMAC (in-house centrifugation protocol), whole blood, and platelet-rich plasma (E-PET; Pall Inc) prepared from 25 horses from 2016 through 2020. Results: Leukocytes, neutrophils, monocytes, lymphocytes, and thrombocytes were increased 4.1-, 3.4-, 4.6-, 4.4-, and 2.5-fold in BMAC compared to BMA, respectively. Interleukin-1 receptor antagonist protein of BMAC was increased 21-fold compared to BMA and increased 117-fold compared to gravity filtration system-based, leukocyte-rich platelet-rich plasma. Conclusions: Laboratory centrifugation enriches the cellular and IL-1Ra concentrations of equine BMAC compared to BMA, with no significant changes in IGF-I, VEGF, PDGF, TGF-β1, IL-6, IL-10, or TNF-α concentrations. Clinical Relevance: Equine BMA and BMAC are patient-side biologics enriched with anti-inflammatory IL-1Ra and support further evaluation of equine BMAC for musculoskeletal tissue healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.